Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | TOP2A | P11388 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
| ▸ | QPCT | Q16769 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15706620 | 0.83 | CSNK2A1 (0.46) | TRPV1CNR1CNR2 | |
| SCHEMBL13088453 | 0.83 | LTA4H (0.44) | TRPV1CNR1CNR2LTA4H | |
| Hydrochloric Acid SCHEMBL3068726 | 0.81 | LTA4H (0.43) | TRPV1CNR1CNR2LTA4H | |
| SCHEMBL13528423 | 0.78 | PSEN1 (0.33) | — | |
| SCHEMBL4414681 | 0.77 | TRPV1 (0.44) | TRPV1CNR1CNR2TOP2ALTA4H | |
| SCHEMBL4408824 | 0.76 | TRPV1 (0.42) | TRPV1CNR1CNR2TOP2ALTA4H | |
| SCHEMBL4407682 | 0.76 | TRPV1 (0.42) | TRPV1CNR1CNR2TOP2A | |
| SCHEMBL4404404 | 0.76 | TRPV1 (0.42) | TRPV1CNR1CNR2TOP2A | |
| SCHEMBL12763765 | 0.76 | TRPV1 (0.46) | TRPV1CNR1CNR2TOP2ASMN1; SMN2 | |
| SCHEMBL4409005 | 0.74 | TRPV1 (0.53) | TRPV1CNR1CNR2TOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024059665-A1 | DIMERIC COMPOUNDS AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| WO-2022198196-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-8293729-B2 | Compounds, pharmaceutical composition and methods relating thereto | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20100099718-A1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROARYL RING, AND ANTIFUNGAL AGENT COMPRISING THE SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100016383-A1 | 4-(3,3-DIHALO-ALLYLOXY)PHENOL DERIVATIVES HAVING PESTICIDAL PROPERTIES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016383-A1 | 4-(3,3-DIHALO-ALLYLOXY)PHENOL DERIVATIVES HAVING PESTICIDAL PROPERTIES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| EP-1859782-B1 | Composition for coloring and/or lightening human hair comprising tetrazoles | HENKEL AG & CO KGAA (DE) | 2009-12-30 | — | — | EP | disclosed |
| US-7608631-B2 | 4-(3,3-dihalo-allyloxy) phenol derivatives having pesticidal properties | SYNGENTA CROP PROTECTION, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608631-B2 | 4-(3,3-dihalo-allyloxy) phenol derivatives having pesticidal properties | SYNGENTA CROP PROTECTION, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| EP-1859782-A1 | Composition for coloring and/or lightening human hair comprising tetrazoles | Henkel Kommanditgesellschaft auf Aktien (DE) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS2, GYS1, PYGL | TRPV1 4858/4885CNR1 4000/4885CNR2 4603/4885 |
| US-20100016383-A1 | 4-(3,3-DIHALO-ALLYLOXY)PHENOL DERIVATIVES HAVING PESTICIDAL PROPERTIES | DDT, QSOX1, SCO2 | TRPV1 2137/4885CNR1 706/4885CNR2 615/4885 |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | MC2R, REN, CYP11B2 | TRPV1 1565/4885CNR1 65/4885CNR2 106/4885 |
| US-20100099718-A1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROARYL RING, AND ANTIFUNGAL AGENT COMPRISING THE SAME | ERG28, CBR3, CBR1 | TRPV1 3981/4885CNR1 485/4885CNR2 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.